Novotech Opens Tokyo CRO Office to Support Japanese Biopharma Sponsors Advancing Into Global Markets

• Novotech, a leading global full-service biotech CRO with 30+ offices across Asia-Pacific, North America, and Europe and partnerships with 7,000+ trial sites, has opened a new office in Tokyo, Japan — building on existing clinical trial operations in the country and strengthening its ability to support Japanese biopharma sponsors seeking to expand programs across international markets.

• The Tokyo office will serve as a strategic CRO hub providing enhanced local expertise, client collaboration, and connectivity to Novotech’s integrated clinical development platform — including early-phase development in Australia, FDA-aligned protocol support, and U.S.-based scientific expertise — under the leadership of Takeshi Mori, newly appointed Country Head for Japan.

Novotech, a leading global full-service biotech CRO and scientific advisory company, has opened a new office in Tokyo, Japan, announced August 23, 2026, from Singapore. The investment strengthens Novotech’s established presence in one of the world’s largest and most sophisticated pharmaceutical markets, building on existing clinical trial activity in Japan and deepening the company’s capacity to serve Japanese biopharma sponsors as they seek to advance programs across Asia-Pacific, the United States, and Europe.

The Tokyo office — located at Shinjuku i-Land Tower in Nishishinjuku — will operate as a strategic hub for Novotech’s Japan operations, providing enhanced local expertise, strengthened collaboration with clients, partners, and research institutions, and direct access to Novotech’s broader global CRO infrastructure. The office is led by Takeshi Mori, appointed as Country Head, Japan, who will oversee local operations and client relationships across the market. Novotech is currently supporting ongoing studies in Japan and provides sponsors with integrated support across early-phase clinical development in Australia, FDA-aligned protocol development, U.S.-based scientific expertise, and international partnering opportunities — a coordinated service model designed to give Japanese biopharma companies a single CRO partner capable of managing cross-border trial complexity without requiring sponsors to engage multiple regional providers.

Japan’s biotech sector is undergoing significant transformation, with an increasing number of emerging and mid-size biopharma companies seeking to internationalize their development programs and bring novel therapies to global markets. Novotech’s expanded Tokyo presence positions the CRO to serve as a bridge between Japan’s sophisticated domestic research base and the international clinical development infrastructure — including patient populations, regulatory pathways, and scientific networks — required to advance programs toward FDA, EMA, and PMDA regulatory submissions. The company’s global operating model is specifically designed for biotech and small- to mid-sized pharmaceutical companies, offering flexible, high-quality clinical development support across therapeutic areas including oncology, rare diseases, CNS disorders, infectious diseases, immunology, and advanced therapies.

The Tokyo office opening follows a series of leadership and strategic investments at Novotech since the start of 2026, including the appointment of Dr. Anand Tharmaratnam as CEO at the start of the year — reflecting the company’s increasingly international profile as it continues to expand its global CRO footprint. Novotech’s Asia-Pacific network, encompassing more than 30 offices and partnerships with over 7,000 trial sites, represents one of the most extensive regional CRO infrastructures available to biotech sponsors seeking to access diverse patient populations and accelerate clinical timelines through multi-geography trial strategies.

“The opening of our Tokyo office is an important milestone for Novotech. Japan is a critical market for global clinical development, and this investment reflects our long-term commitment to building strong local capabilities while delivering high-quality services to our clients.”

Takeshi Mori, Country Head Japan, Novotech